MENU

Reducing the negative effects of drug eluting stents

Development of a stent with a biodegradable coating and a lower dose of drugs to reduce repetitive narrowing of bloodvessels in delivering anti-immune systems or anti-cancer drugs and to better regulate the medicine delivery curve.

Using a catheter, a balloon will be positioned in the narrowing of a bloodvessel. The balloon is inflated so the narrowing of the bloodvessel opens. With a similar catheter, a stent will be positioned in a bloodvessel to prevent re-narrowing of the vessel. During expansion and placement of the stent, the bloodvessel is damaged. The narrowed bloodvessel will be stretched to its original diameter (between 3 and 5 mm). The narrowing will be pushed into the bloodvessel with a relatively large force. By doing so the inner layer of the bloodvessel will be damaged and cracks in the bloodvessel are an unfortunate side effect. The bloodvessel will be irritated and a defence reaction generated against the metal on the surface of the stent. A biodegradable polymer layer will be placed on the stent surface by dipcoating or spraying. The objective of this project is to determine which of the two methods is preferable. The polymer will be mixed or bounded with a medicine. The choice of medicine used is related to the way in which the medicine influences the cycle of cell growth. There are different types of medicine: * Suppressors of the immune system * Cell-killers (cancer) * Repairers of the bloodvessel inner layer (endothelium) * Opponents of irritation. The medicine does not cure, but the body itself does. Under the influence of the medicine, smooth muscle cell proliferation is reduced or prevented. The medicine delivery is linked to the bio-absorption of the polymer layer. The polymer layer breaks down in human material elements during absorption and is naturally absorbed by the bloodstream. Research will be done on the combination coating/polymer including prototyping. The prototypes will be tested both in animal models as well as in human trials. Cardiologists in hospitals all over the world will cooperate in the research. Keywords: drug, eluting, stent.
Acronym: 
DRUG ELUTING STENT
Project ID: 
3 147
Start date: 
01-07-2003
Project Duration: 
46months
Project costs: 
180 000.00€
Technological Area: 
Heart and blood circulation illnesses
Market Area: 
Other therapeutic (including defibrillators)

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.